Member Info for kenny100

Reads zero trades...........

Apollon Formularies Plc (APOL.PL) 7.25 0 11.54% 7.25 7.25

https://ukinvestormagazine.co.uk/aquis-reverse-takeover-apollon-formularies-plc/

Apollon Formularies
@apollon_uk
·
8m
Aquis reverse takeover Apollon Formularies

The long-term strategy is to go from growing cannabis all the way through to developing cannabis-based drugs. There is an underlying value of the licences and the infrastructure already in place.

https://twitter.com/apollon_uk

4 years ago.............................

https://99designs.co.uk/product-label-design/contests/apollon-formularies-cbd-cream-678398

Need to get products to market, the time of tweets and what may happen in the future hold no interest to me at this stage.
Its a hard six months for any new companies to list in the UK, need to push ahead as a first mover.... IMHO

https://www.ig.com/uk/news-and-trade-ideas/uk-cannabis-shares-companies-regulation-190918#information-banner-dismiss

Yesterday ...... Market Cap: £65,482,959

Today ............... Market Cap: £54,257,309

Down................. £ 11.2 million.............. DYOR

.

Info from last month....... DYOR

Going forward, the company is looking at potential “third-party sales agreements” for Apollon products in countries such as South Africa and Greece, says Jacobs.

Corporate developments may include ‘up listing’ here in the UK and taking a stock market quote in the US, most likely on the OTC QB.

Jacobs says the company has news flow “coming thick and fast” after the RTO.

https://twitter.com/apollon_uk

Going forward, the company is looking at potential “third-party sales agreements” for Apollon products in countries such as South Africa and Greece, says Jacobs.

Corporate developments may include ‘up listing’ here in the UK and taking a stock market quote in the US, most likely on the OTC QB.

Jacobs says the company has news flow “coming thick and fast” after the RTO.

Formulations are, and will continue to be, patented.

https://www.apollon.org.uk/operations/medically-supervised-trials

Exclusivity on some of Docs patents hopefully.....................

https://www.youtube.com/watch?v=_R3wRIWeCzY

Maybe the Doc in the background????????????

https://www.youtube.com/watch?v=n3LJatp1slk

5 views only....................

https://www.youtube.com/watch?v=p-mVzWbar9U

Market Cap: £65,482,959

Info.................. BOD needs updating twitter link still for AfriAG

https://www.aquis.eu/aquis-stock-exchange/companies-and-prices

https://www.aquis.eu/aquis-stock-exchange/member?securityidaqse=APOL

ETAILS OF ANY LOCK-IN ARRANGEMENTS:
A lock-in agreement was executed by and among the Company, the Proposed Directors, Apollon
Formularies, Inc. and Roderick McIllree and Peterhouse, pursuant to which the Proposed Directors, Apollon
Formularies, Inc. and Roderick McIllree have undertaken, save in certain circumstances, not to sell or
otherwise dispose of or agree to sell or dispose of any of their interests (direct or indirect) in the Ordinary
Shares held by them (or subsequently acquired by them) for a period of twelve months commencing on the
date of Admission (“Lock-in Period”). In addition, the Proposed Directors, Apollon Formularies, Inc. and
Roderick McIllree have undertaken to the Company and Peterhouse not to dispose of their Ordinary Shares
for a period of 12 months after the end of the Lock-in Period without first consulting the Company and
Peterhouse in order to maintain an orderly market for the Ordinary Shares. The Proposed Directors, Apollon
Formularies, Inc. and Roderick McIllree will hold in aggregate 413,483,412 Ordinary Shares representing
55.25 per cent. of the Enlarged Share Capital, on Admission.